An attorney’s experience with cannabis depends in part on their age, according to a recent survey by Bloomberg Law. Generational differences in cannabis use illustrate how its changing legal landscape is creating a more cannabis-friendly generation of lawyers.
The pharmaceutical industry is operating within a marketplace of heightened risk, according to a Bloomberg Law analysis of Form 10-K filings. But pharma companies aren’t changing their risk governance approach, clearly favoring board oversight over other recommended means.
Cannabis’s move to Schedule III of the federal Controlled Substances Act marks a turning point for pharmaceutical companies’ investment in cannabis drug development by removing barriers that deterred them from cannabis under Schedule I and unlocking a lucrative new federal market for cannabis-based prescription drugs.
Biotechnology start-ups burn through cash quickly as they spend money trying to develop successful drugs. When investors turn more risk averse, as in recent years, biotechs look in alternative places for capital, including from private investment in public equity (PIPEs) and via follow-on offerings.
Deal volumes for pharmaceutical deals were lower in 2023 than they were 10 years ago and have been lower, on average, than the years prior to 2018 and 2019’s highs. Despite signs that deals may have been on an upswing heading into 2024, this year’s numbers so far aren’t encouraging.
Bloomberg Law asked its legal analysts to identify emerging issues and data-driven trends that are important to lawyers who work in or advise the pharmaceutical industry. The results of their research can be seen in the following collection of seven analysis pieces.
An attorney’s experience with cannabis depends in part on their age, according to a recent survey by Bloomberg Law. Generational differences in cannabis use illustrate how its changing legal landscape is creating a more cannabis-friendly generation of lawyers.
Deal volumes for pharmaceutical deals were lower in 2023 than they were 10 years ago and have been lower, on average, than the years prior to 2018 and 2019’s highs. Despite signs that deals may have been on an upswing heading into 2024, this year’s numbers so far aren’t encouraging.
The pharmaceutical industry is operating within a marketplace of heightened risk, according to a Bloomberg Law analysis of Form 10-K filings. But pharma companies aren’t changing their risk governance approach, clearly favoring board oversight over other recommended means.
Cannabis’s move to Schedule III of the federal Controlled Substances Act marks a turning point for pharmaceutical companies’ investment in cannabis drug development by removing barriers that deterred them from cannabis under Schedule I and unlocking a lucrative new federal market for cannabis-based prescription drugs.
Biotechnology start-ups burn through cash quickly as they spend money trying to develop successful drugs. When investors turn more risk averse, as in recent years, biotechs look in alternative places for capital, including from private investment in public equity (PIPEs) and via follow-on offerings.
New survey data from Bloomberg Law indicates that education on well-being, mental health, and substance use in the legal profession is available to attorneys—but attorneys aren’t using it.
The IPO market continues its volatile ways but the pace of offerings improved in the third quarter and there are reasons that the market is likely to improve in 2025.
There was a Q2-to-Q3 increase in global mergers and acquisitions deal volumes in 2024, yet dealmakers will likely face headwinds through the end of the year, so the traditional end-of-year rally may not materialize.
Young lawyers are suffering more well-being problems, such as anxiety and depression, than their older colleagues, according to recent survey results from Bloomberg Law. But they also may be the age group best at getting the help that they need to overcome those issues.
Get the latest legal, regulatory, and enforcement news and analysis, as well as in-depth business and industry covering in the following areas: